Edition:
United Kingdom

Vertex Pharmaceuticals Inc (VRTX.OQ)

VRTX.OQ on NASDAQ Stock Exchange Global Select Market

141.68USD
11 Dec 2017
Change (% chg)

$-1.93 (-1.34%)
Prev Close
$143.61
Open
$143.73
Day's High
$143.91
Day's Low
$139.80
Volume
479,563
Avg. Vol
502,090
52-wk High
$167.70
52-wk Low
$71.50

Latest Key Developments (Source: Significant Developments)

Vertex Announces Positive Results From Open-Label Phase 3 Study Of KALYDECO(ivacaftor)
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Vertex Pharmaceuticals Inc ::VERTEX ANNOUNCES POSITIVE RESULTS FROM OPEN-LABEL PHASE 3 STUDY OF KALYDECO® (IVACAFTOR) IN CHILDREN WITH CYSTIC FIBROSIS AGES 1 TO 2 YEARS.VERTEX PHARMACEUTICALS - KALYDECO​ ‍STUDY MET PRIMARY SAFETY ENDPOINT, SHOWED IMPROVEMENTS ACROSS MULTIPLE ENDPOINTS.VERTEX PHARMACEUTICALS - ‍ARRIVAL STUDY GENERALLY WELL TOLERATED, SAFETY DATA WERE CONSISTENT WITH THOSE SEEN IN PREVIOUS PHASE 3 STUDIES OF IVACAFTOR​.VERTEX PHARMACEUTICALS INC - ‍VERTEX PLANS TO SUBMIT APPLICATIONS FOR IVACAFTOR TO FDA AND EMA IN Q1 OF 2018​.  Full Article

Vertex reports Q3 non-GAAP earnings per share $0.53
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Vertex Pharmaceuticals Inc :Vertex reports third-quarter 2017 financial results.Q3 non-GAAP earnings per share $0.53.Q3 GAAP loss per share $0.41.Q3 earnings per share view $0.31 -- Thomson Reuters I/B/E/S.Vertex Pharmaceuticals Inc says ‍third-quarter 2017 cystic fibrosis product revenues of $550 million, up 34% versus Q3 2016​.Says ‍increased its total 2017 CF product revenue guidance, including ORKAMBI and KALYDECO revenue guidance​.Vertex Pharmaceuticals Inc qtrly ‍product revenues for ORKAMBI $336 million and $213 million for KALYDECO​.Says ‍reiterated its 2017 combined GAAP and non-GAAP research and development and SG&A expense guidance​.Says ‍now expects total 2017 CF product revenues of $2.10 to $2.15 billion​.Vertex Pharmaceuticals Inc ‍increases FY ORKAMBI revenue guidance to $1.29 to $1.32 billion and KALYDECO revenue guidance to $810 to $830 million​.  Full Article

Vertex Pharmaceuticals says FTC requested for additional information on pending acquisition from Concert Pharmaceuticals
Monday, 22 May 2017 

May 22 (Reuters) - Concert Pharmaceuticals Inc :Vertex Pharmaceuticals says on May 19, the U.S. FTC issued a request for additional information in connection co's pending acquisition of CTP-656 and other assets from Concert Pharmaceuticals.The second request was issued under notification requirements of the Hart-Scott-Rodino antitrust improvements act.Vertex Pharmaceuticals says it intends to work cooperatively with the FTC as it reviews the transaction.  Full Article

Vertex Pharma: Amended and expanded agreement with Cystic Fibrosis Foundation Therapeutics
Friday, 14 Oct 2016 

Vertex Pharmaceuticals Inc : Vertex Pharma - on oct 13 amended and expanded research, development and commercialization agreement with cystic fibrosis foundation therapeutics inc . Vertex Pharma - amendment provides for upfront program award from cfft to us of $75.0 million,development funding from cfft to us of upto $6.0 million annually . Vertex Pharmaceuticals Inc- pursuant to amendment , co will continue to pay royalties ranging from low single digits to mid-single digits .Vertex Pharma-entered into data license deal with Cystic Fibrosis Foundation, co will pay for continuing access to data from CFF's patient registry.  Full Article

Vertex enrollment complete in Phase 3 study in people with two copies of F508DEL mutation
Monday, 15 Aug 2016 

Vertex : Provides update on ongoing phase 3 program For VX-661 in combination with ivacaftor for the treatment of cystic fibrosis . Enrollment complete in phase 3 study in people with two copies of F508DEL mutation . Enrollment expected to be completed in September in phase 3 study in people with one F508DEL mutation, one residual function mutation .Plans to submit new drug application (NDA) to FDA for vx-661 in combination with ivacaftor in second half of 2017.  Full Article

Vertex Pharmaceuticals says reiterates 2016 guidance
Wednesday, 27 Jul 2016 

Vertex Pharmaceuticals Inc : Vertex pharmaceuticals inc says reiterates 2016 guidance for orkambi product revenues of $1.0 to $1.1 billion . Gaap research and development and sg&a expenses . Vertex reports second quarter 2016 financial results . Q2 non-gaap earnings per share $0.24 . Q2 gaap loss per share $0.26 . Q2 earnings per share view $0.21 -- Thomson Reuters I/B/E/S .Vertex pharmaceuticals inc says reiterates 2016 guidance for kalydeco product revenues of $685 to $705 million.  Full Article

Vertex Pharmaceuticals and Moderna collaborate to discover and develop MRNA Therapeutics for cystic fibrosis
Wednesday, 6 Jul 2016 

Vertex Pharmaceuticals Inc : Vertex and Moderna establish exclusive collaboration to discover and develop mrna therapeutics(tm) for cystic fibrosis . Vertex will also pay Moderna future development and regulatory milestones of up to $275 million . Vertex Pharmaceuticals says $275 million payment, including $220 million in reimbursement milestones, as well as tiered royalty payments on future sales . Vertex Pharmaceuticals Inc says Moderna to receive $40 million upfront, made up of a $20 million cash payment and a $20 million convertible note investment . Vertex and Moderna will conduct exclusive research, development and commercialization activities to advance mrna therapeutics . Will lead all preclinical, development and commercialization activities associated with advancement of mrna therapeutics .Will fund all expenses related to collaboration.  Full Article

Vertex Pharma says target review date of Sept. 30 set for FDA's decision on application
Tuesday, 31 May 2016 

Vertex Pharmaceuticals Inc : Target review date of september 30, 2016 set for fda's decision on application .u.s. Fda accepts for priority review supplemental new drug application for the use of orkambi® (lumacaftor/ivacaftor) in children with cystic fibrosis ages 6 to 11 who have two copies of the f508del mutation.  Full Article

Spero Therapeutics to acquire worldwide rights to Vertex's VXC-486/VXC-100
Wednesday, 25 May 2016 

Spero Therapeutics LLC : Has entered into an agreement with Vertex Pharmaceuticals . Deal to acquire worldwide rights to VXC-486/VXC-100 and a portfolio of innovative antibacterial compounds . Under terms of agreement, Spero will make an upfront payment to Vertex for portfolio rights . Under terms of agreement, Spero will assume responsibility for drug development and bringing compounds to market .Vertex will be eligible to get future devpt,commercial milestones, royalties on any therapeutic products resulting from agreement.  Full Article

Vertex receives Australian approval for Orkambi
Tuesday, 8 Mar 2016 

Vertex Pharmaceuticals Inc:Receives Australian approval for Orkambi® (lumacaftor/ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis in people ages 12 and older with two copies of the f508del mutation.Says Therapeutic Goods Administration (TGA) of Australia has approved Orkamb.  Full Article

Photo

Tax-loss selling to pressure 2017's losers in December

NEW YORK Stocks that have been lackluster so far in 2017 are unlikely to see their fortunes reversed in the final month of the year, as investors engage in tax-harvesting practices before the new year.